TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Living Cell Technologies ( (AU:1AI) ) has shared an update.
Algorae Pharmaceuticals has signed an exclusive licensing agreement with Sakar Healthcare to launch five generic oncology medicines in Australia and New Zealand, marking its first commercial presence in these markets. This strategic move complements Algorae’s ongoing R&D initiatives and leverages Sakar’s manufacturing capabilities, aiming to enhance patient access to high-quality oncology treatments and position Algorae for long-term growth.
More about Living Cell Technologies
Algorae Pharmaceuticals is an AI-enabled pharmaceutical development company that focuses on discovering and developing drug synergies for unmet medical needs. The company utilizes its proprietary AI platform, AlgoraeOS, to identify synergistic drug combinations with transformative therapeutic potential. Algorae collaborates with research institutions and pharmaceutical partners to accelerate the translation of AI-predicted therapies into the clinic and is publicly traded on the Australian Stock Exchange.
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$12.66M
Learn more about 1AI stock on TipRanks’ Stock Analysis page.